Toll Free: 1-888-928-9744

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 56 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Metastatic Uveal Melanoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides an overview of the Metastatic Uveal Melanoma (Oncology) pipeline landscape.

Metastatic uveal melanoma is a cancer that has spread from the eye (uveal) to other parts of the body. The most common site of metastasis for uveal melanoma is the liver. Other common sites of metastasis include the lung, bones and just beneath the skin (subcutaneous). Symptoms include jaundice, itchy skin or rash, abnormally high enzymes in the liver, abdominal pain, appetite loss, nausea, and vomiting. Treatment includes surgery, chemotherapy and radiation therapy. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Uveal Melanoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Uveal Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Uveal Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Uveal Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Metastatic Uveal Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Uveal Melanoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Metastatic Uveal Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Metastatic Uveal Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Metastatic Uveal Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Uveal Melanoma (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Metastatic Uveal Melanoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Metastatic Uveal Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metastatic Uveal Melanoma Overview 6 Therapeutics Development 7 Pipeline Products for Metastatic Uveal Melanoma - Overview 7 Pipeline Products for Metastatic Uveal Melanoma - Comparative Analysis 8 Metastatic Uveal Melanoma - Therapeutics under Development by Companies 9 Metastatic Uveal Melanoma - Therapeutics under Investigation by Universities/Institutes 10 Metastatic Uveal Melanoma - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Metastatic Uveal Melanoma - Products under Development by Companies 13 Metastatic Uveal Melanoma - Products under Investigation by Universities/Institutes 14 Metastatic Uveal Melanoma - Companies Involved in Therapeutics Development 15 Bellicum Pharmaceuticals Inc 15 Celldex Therapeutics Inc 16 Eli Lilly and Company 17 Novartis AG 18 Spectrum Pharmaceuticals Inc 19 Metastatic Uveal Melanoma - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 alpelisib - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 BPX-701 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 emibetuzumab - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 glembatumumab vedotin - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 KCN-1 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 LXS-196 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 merestinib - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 sotrastaurin acetate - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 vincristine sulfate - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Metastatic Uveal Melanoma - Dormant Projects 51 Metastatic Uveal Melanoma - Discontinued Products 52 Metastatic Uveal Melanoma - Product Development Milestones 53 Featured News & Press Releases 53 Apr 18, 2016: Celldex Therapeutics Presents data on Glembatumumab Vedotin at AACR 2016 53 Jan 11, 2016: Bellicum Pharmaceuticals Announces Submission of BPX-701 Clinical Trial Protocols for Review by the NIH RAC 53 Appendix 55 Methodology 55 Coverage 55 Secondary Research 55 Primary Research 55 Expert Panel Validation 55 Contact Us 55 Disclaimer 56
List of Tables
Number of Products under Development for Metastatic Uveal Melanoma, H2 2016 7 Number of Products under Development for Metastatic Uveal Melanoma - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Metastatic Uveal Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 15 Metastatic Uveal Melanoma - Pipeline by Celldex Therapeutics Inc, H2 2016 16 Metastatic Uveal Melanoma - Pipeline by Eli Lilly and Company, H2 2016 17 Metastatic Uveal Melanoma - Pipeline by Novartis AG, H2 2016 18 Metastatic Uveal Melanoma - Pipeline by Spectrum Pharmaceuticals Inc, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Number of Products by Stage and Target, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 24 Number of Products by Stage and Route of Administration, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 28 Metastatic Uveal Melanoma - Dormant Projects, H2 2016 51 Metastatic Uveal Melanoma - Discontinued Products, H2 2016 52



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify